

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Purified Anti-Mouse CD28 (37.51)

RRID:AB_2621492

Type: Antibody

Proper Citation

Tonbo Biosciences Cat# 70-0281, RRID:AB_2621492

Antibody Information

URL: http://antibodyregistry.org/AB_2621492

Proper Citation: Tonbo Biosciences Cat# 70-0281, RRID:AB_2621492

Target Antigen: CD28

Clonality: monoclonal

Comments: Original manufacturer of this product; Applications: FC,IP Dilution: This purified format is guaranteed to be >90% pure as determined by SDS-PAGE analysis. Citations are provided as a convenience to you - please consult Materials and Methods sections for additional details about the use of any product in these publications.

Antibody Name: Purified Anti-Mouse CD28 (37.51)

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: 37.51

Antibody ID: AB_2621492

Vendor: Tonbo Biosciences

Catalog Number: 70-0281

Alternative Catalog Numbers: OWL-A11512

Record Creation Time: 20250820T062909+0000

Record Last Update: 20250821T001455+0000

Ratings and Alerts

No rating or validation information has been found for Purified Anti-Mouse CD28 (37.51).

No alerts have been found for Purified Anti-Mouse CD28 (37.51).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Appleton BD, et al. (2023) Oxidized Phospholipid oxPAPC Alters Regulatory T-Cell Differentiation and Decreases Their Protective Function in Atherosclerosis in Mice. *Arteriosclerosis, thrombosis, and vascular biology*, 43(11), 2119.

Runtsch MC, et al. (2022) Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages. *Cell metabolism*, 34(3), 487.

Chaurio RA, et al. (2022) TGF- β -mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. *Immunity*, 55(1), 115.

Angiari S, et al. (2020) Pharmacological Activation of Pyruvate Kinase M2 Inhibits CD4⁺ T Cell Pathogenicity and Suppresses Autoimmunity. *Cell metabolism*, 31(2), 391.

Effern M, et al. (2020) Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. *Immunity*, 53(3), 564.